Abstracts tagged "rheumatoid arthritis (RA) and statins"

Abstract Number: 11 • 2016 ACR/ARHP Annual Meeting
Drug Prescribing Trends in Adults with Rheumatoid Arthritis: A Population-Based Comparative Study from 2005-2014
Alex Zamora-Legoff¹, Cynthia S. Crowson², Eric L. Matteson³, Sara J. Achenbach⁴ and Elena Myasoedova³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: To examine drug prescribing trends for patients with rheumatoid arthritis (RA) over recent years and compare them to matched non-RA subjects. Methods: Retrospective prescription…
Abstract Number: 3023 • 2016 ACR/ARHP Annual Meeting
Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies
Iain B. McInnes¹, Joel Kremer², Paul Emery³, Steven H. Zuckerman⁴, Giacomo Ruotolo⁴, Chadi Saifan⁴, Lei Chen⁴, Shayami Thanabalasundrum⁴, Sarah Witt⁴ and William Macias⁴, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain, ²The Center for Rheumatology, Albany Medical College, Albany, NY, ³University of Leeds, Midlothian, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: In patients with active RA an increase in lipid analytes has been observed after treatment with janus kinase inhibitors and other disease-modifying antirheumatic drugs.1…
Abstract Number: 591 • 2015 ACR/ARHP Annual Meeting
Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis
Eirik Ikdahl¹, Jonny Hisdal², Silvia Rollefstad¹, Inge C Olsen³, Tore K. Kvien⁴, Terje R. Pedersen⁵ and Anne Grete Semb⁶, ¹Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Preventive Cardiology, Ullevaal University Hospital, Oslo, Norway, ⁶Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Endothelial dysfunction is an early step in the formation of atherosclerotic lesions and can be quantified by the degree of flow mediated vasodilation (FMD)…
Abstract Number: 1502 • 2015 ACR/ARHP Annual Meeting
Initiating Statin Medication and Risk of Fatigue in Rheumatoid Arthritis
James S. Andrews¹, Harlan Sayles², Kaleb Michaud³ and Patricia P. Katz⁴, ¹Rheumatology, University of California San Francisco, San Francisco, CA, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, UCSF, SF, CA
Background/Purpose: Fatigue is common in Rheumatoid Arthritis (RA) and has a major impact on quality of life. Individuals with RA are also at increased risk…
Abstract Number: 2126 • 2015 ACR/ARHP Annual Meeting
Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis
George D. Kitas¹, Peter Nightingale², Jane Armitage³, Naveed Sattar⁴, Jill Belch⁵, Deborah P.M. Symmons⁶ and TRACE RA Consortium, ¹Dudley Group NHS Foundation Trust, Dudley, and Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Clinical Trial Service Unit and Epidemiology Unit, University of Oxford, Oxford, United Kingdom, ⁴University of Glasgow, BHF Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom, ⁵Division of Cardiovascular and Diabetes Medicine, University of Dundee, Dundee, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease (CVD) compared to the general population, both due to classical and novel…
Abstract Number: 2829 • 2013 ACR/ARHP Annual Meeting
Statin Adherence and Risk Of Mortality In Patients With Rheumatoid Arthritis: A Population-Based Study
Mary De Vera^1,2, Michal Abrahamowicz³ and Diane Lacaille⁴, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: Poor adherence with statin therapy is associated with increased mortality in the general population, but no corresponding data are available among patients with rheumatoid…
Abstract Number: 2765 • 2013 ACR/ARHP Annual Meeting
A Double-Blind Randomized Placebo-Controlled Trial Of Lovastatin in Patients with Rheumatoid Arthritis
Cynthia Aranow¹, John J. Cush², Marcy B. Bolster³, Christopher C. Striebich⁴, Maria Dall'era⁵, Meggan Mackay⁶, Ewa Olech⁷, Tracy M. Frech⁸, J. Box⁹, Richard M. Keating¹⁰, Mary Chester M. Wasko¹¹, E. William St Clair¹², Alan Kivitz¹³, Betty Diamond¹⁴, Anne Davidson¹⁵, Meagan Spychala¹⁶, Ellen A. Goldmuntz¹⁷ and Autoimmunity Centers of Excellence¹⁸, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ³Medicine, Medical University of South Carolina, Charleston, SC, ⁴University of Colorado Denver, Aurora, CO, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁹Carolina Bone and Joint, Charlotte, NC, ¹⁰Rheumatology Section, The University of Chicago, Chicago, IL, ¹¹West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, ¹²Medicine, Duke Unversity Medical Center, Durham, NC, ¹³Altoona Center for Clinical Research, Duncansville, PA, ¹⁴Autoimmune & Musculoskeletal, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁶Rho, Inc., Chapel Hill, NC, ¹⁷DAIT, NIAID/NIH, Bethesda, MD, ¹⁸NIAID, National Institutes of Health, Bethesda, MD
Background/Purpose: HMG -CoA reductase inhibitors (statins) are standard treatment for hyperlipidemia. In addition to lipid lowering abilities, statins exhibit multiple anti-inflammatory effects. The objectives of…
Abstract Number: 1249 • 2012 ACR/ARHP Annual Meeting
The Impact of Statin Use On Lipid Levels in Statin-Naive Patients with Rheumatoid Arthritis (RA) Vs. Non-RA Subjects: Results From a Population-Based Study
Elena Myasoedova¹, Cynthia S. Crowson², Abigail B. Green², Eric L. Matteson³ and Sherine E. Gabriel⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Dyslipidemia in patients with rheumatoid arthritis (RA) is well recognized. The impact of lipid-lowering medications on lipid levels in patients with RA vs non-RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].